ES2857998T3 - Receptores de antígenos quiméricos - Google Patents

Receptores de antígenos quiméricos Download PDF

Info

Publication number
ES2857998T3
ES2857998T3 ES16748518T ES16748518T ES2857998T3 ES 2857998 T3 ES2857998 T3 ES 2857998T3 ES 16748518 T ES16748518 T ES 16748518T ES 16748518 T ES16748518 T ES 16748518T ES 2857998 T3 ES2857998 T3 ES 2857998T3
Authority
ES
Spain
Prior art keywords
car
cells
domain
cell
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16748518T
Other languages
English (en)
Spanish (es)
Inventor
Shinya Tanaka
Naoto Hirano
Yuki Kagoya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Takara Bio Inc
Original Assignee
University Health Network
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network, Takara Bio Inc filed Critical University Health Network
Application granted granted Critical
Publication of ES2857998T3 publication Critical patent/ES2857998T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epidemiology (AREA)
ES16748518T 2015-02-12 2016-02-11 Receptores de antígenos quiméricos Active ES2857998T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562115527P 2015-02-12 2015-02-12
PCT/CA2016/050126 WO2016127257A1 (en) 2015-02-12 2016-02-11 Chimeric antigen receptors

Publications (1)

Publication Number Publication Date
ES2857998T3 true ES2857998T3 (es) 2021-09-29

Family

ID=56614021

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16748518T Active ES2857998T3 (es) 2015-02-12 2016-02-11 Receptores de antígenos quiméricos

Country Status (7)

Country Link
US (2) US10336810B2 (https=)
EP (1) EP3256496B1 (https=)
JP (2) JP6846352B2 (https=)
KR (1) KR102607152B1 (https=)
CA (1) CA2974998C (https=)
ES (1) ES2857998T3 (https=)
WO (1) WO2016127257A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2857998T3 (es) 2015-02-12 2021-09-29 Univ Health Network Receptores de antígenos quiméricos
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
GB201518816D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Receptor
EP3458485B1 (en) * 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
NZ750256A (en) 2016-08-03 2026-02-27 Dipersio John F Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
JP7206214B2 (ja) * 2016-12-13 2023-01-17 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
WO2019169290A1 (en) 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
WO2019175328A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4pathwayactivationandusethereoffortreatingcancer
CA3091490A1 (en) 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Rapamycin resistant cells
CA3098014A1 (en) * 2018-04-27 2019-10-31 Crispr Therapeutics Ag Anti-bcma car-t-cells for plasma cell depletion
CN110615843B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用
GB201814203D0 (en) * 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
WO2020050667A1 (ko) * 2018-09-05 2020-03-12 공석경 고형암을 위한 키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포
KR20210132668A (ko) * 2019-02-21 2021-11-04 아르벨 리미티드 인공 면역감시 키메라 항원 수용체(ai-car) 및 이를 발현하는 세포
EP3931208A1 (en) 2019-03-01 2022-01-05 Allogene Therapeutics, Inc. Chimeric cytokine receptors bearing a pd-1 ectodomain
BR112021017365A2 (pt) 2019-03-01 2022-02-01 Allogene Therapeutics Inc Receptores de citocina quiméricos constitutivamente ativos
GB201911187D0 (en) * 2019-08-05 2019-09-18 Autolus Ltd Receptor
GB201912515D0 (en) * 2019-08-30 2019-10-16 King S College London Engineered regulatory T cell
WO2021041806A1 (en) 2019-08-30 2021-03-04 Allogene Therapeutics, Inc. Chimeric cytokine receptors comprising tgf beta binding domains
CN114761424B (zh) * 2019-09-05 2025-09-19 波赛达治疗公司 同种异体细胞组合物和使用方法
CN110717956B (zh) * 2019-09-30 2023-06-20 重庆大学 一种有限角投影超像素引导的l0范数最优化重建方法
TWI717880B (zh) 2019-10-24 2021-02-01 中國醫藥大學附設醫院 Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物
CA3166420A1 (en) * 2020-01-14 2021-07-22 Synthekine, Inc. Il2 orthologs and methods of use
CN115038453A (zh) * 2020-01-14 2022-09-09 辛德凯因股份有限公司 具有改变的icd stat信号转导的cd122
JP2023514407A (ja) 2020-02-24 2023-04-05 アロジーン セラピューティクス，インコーポレイテッド 増強された活性を有するｂｃｍａ ｃａｒ－ｔ細胞
CN115427440A (zh) * 2020-02-25 2022-12-02 圭尔医疗有限公司 用于工程化细胞的嵌合受体
WO2021183795A1 (en) * 2020-03-11 2021-09-16 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
KR20230011948A (ko) * 2020-04-17 2023-01-25 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 향상된 기능을 갖는 면역 세포
EP4139345A1 (en) * 2020-04-24 2023-03-01 Sorrento Therapeutics, Inc. Memory dimeric antigen receptors
KR102297396B1 (ko) 2020-07-29 2021-09-06 (주)티카로스 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
EP4261225A4 (en) 2020-12-10 2024-11-13 Eutilex Co., Ltd. ANTI-PD-1 ANTIBODY AND ITS USES
CN114716548B (zh) 2021-01-05 2024-11-05 (株)爱恩德生物 抗-fgfr3抗体及其用途
CN113512125B (zh) * 2021-04-26 2024-01-19 北京双赢科创生物科技有限公司 一种携带stat结合基序的嵌合抗原受体分子及表达该嵌合抗原受体分子的nk细胞
WO2023044457A1 (en) 2021-09-17 2023-03-23 Parker Institute For Cancer Immunotherapy Switch receptors using il-9 signaling domains
WO2023159000A2 (en) * 2022-02-15 2023-08-24 Memorial Sloan-Kettering Cancer Center Compositions including cytotoxic innate lymphoid cells and uses therof
WO2023158997A2 (en) * 2022-02-15 2023-08-24 Memorial Sloan-Kettering Cancer Center Compositions including killer innate-like t cells and uses therof
US20250319131A1 (en) * 2022-07-11 2025-10-16 The Board Of Trustees Of The Leland Stanford Junior University Tunable cytokine receptor signaling domains
IL318546A (en) 2022-07-26 2025-03-01 Aimed Bio Inc Anti-ROR1 antibody and its uses
EP4342907A1 (en) 2022-09-21 2024-03-27 AvenCell Europe GmbH Switchable chimeric antigen receptors and their use
EP4593871A1 (en) 2022-09-30 2025-08-06 Caribou Biosciences, Inc. Anti-ror1 chimeric antigen receptors (cars), car-nk cells and related methods
EP4633648A1 (en) * 2022-12-15 2025-10-22 Carisma Therapeutics Inc. Chimeric antigen receptors including jak/stat binding domains and modified immune cells
WO2025096673A1 (en) * 2023-10-30 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising cells targeting cancer and methods of using the same
WO2026006794A1 (en) * 2024-06-27 2026-01-02 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptors and uses thereof
WO2026024468A1 (en) 2024-07-26 2026-01-29 Caribou Biosciences, Inc. Modular linked chimeric antigen receptors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US6077947A (en) 1995-02-02 2000-06-20 Cell Genesys, Inc. DNA encoding an intracellular chimeric receptor comprising Janus kinase
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
EP1795599A1 (en) 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
WO2010089412A1 (en) 2009-02-09 2010-08-12 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
US9746470B2 (en) 2011-05-09 2017-08-29 Whitehead Institute For Biomedical Research Chaperone interaction assays and uses thereof
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
EP3783098A1 (en) * 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
AU2014268364A1 (en) * 2013-05-24 2015-12-10 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
ES2857998T3 (es) 2015-02-12 2021-09-29 Univ Health Network Receptores de antígenos quiméricos

Also Published As

Publication number Publication date
US10822392B2 (en) 2020-11-03
KR102607152B1 (ko) 2023-11-27
JP6846352B2 (ja) 2021-03-24
US10336810B2 (en) 2019-07-02
CA2974998A1 (en) 2016-08-18
US20190359685A1 (en) 2019-11-28
CA2974998C (en) 2022-04-26
WO2016127257A1 (en) 2016-08-18
JP2021036883A (ja) 2021-03-11
EP3256496A1 (en) 2017-12-20
US20180037630A1 (en) 2018-02-08
EP3256496A4 (en) 2018-12-12
KR20170116084A (ko) 2017-10-18
JP2018509893A (ja) 2018-04-12
EP3256496B1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
ES2857998T3 (es) Receptores de antígenos quiméricos
AU2024200592B2 (en) Chimeric antigen receptors and methods of use thereof
US20240390496A1 (en) Single-chain and multi-chain synthetic antigen receptors for diverse immune cells
JP2023145589A (ja) 共刺激のための新規のプラットフォーム、新規のｃａｒ設計、および養子細胞療法のための他の増強
AU2016313082B2 (en) Chimeric antigen receptors with integrated controllable functions
JP2022522654A (ja) Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体
KR20220124173A (ko) Lilrb1-기반 키메라 항원 수용체
CN110072885A (zh) TGFβ信号转换器
AU2015367317A1 (en) Inhibitory chimeric antigen receptor (iCAR or N-CAR) expressing non-T cell transduction domain
JP2022512475A (ja) 二量体化剤調節免疫受容体複合体
KR20200108285A (ko) Nkg2d daric 수용체
US20230192848A1 (en) Engineered cell compositions and methods of use thereof
TW202246504A (zh) 靶向嵌合抗原受體之ｒｏｒ１
US20220267420A1 (en) Foxp3 targeting agent compositions and methods of use for adoptive cell therapy
TW202239768A (zh) 改良之免疫細胞療法
US20260014199A1 (en) Modified immune cells
JP2024502170A (ja) 癌のための改良された養子細胞移植療法
KR20240069766A (ko) Il5ra 세포 표면 마커
TW202513578A (zh) 用於治療免疫病症之組合物及方法
CN117412985A (zh) 靶向ror1的嵌合抗原受体